Progyny

Progyny, Inc. is a fertility benefits management company. It provides fertility solutions to employers, managing IUI, in vitro fertilization (IVF), egg freezing, and other fertility treatments. It operates through one segment: fertility and pharmacy benefits solutions. It also delivers treatment services and access to the firm’s network of fertility specialist. The company was founded on April 3, 2008 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Progyny reports record growth in 2022, eyes sustained success

Progyny's exceptional performance in 2022, driven by record revenue growth and client additions, positions the company for continued success in 2023.
The company's strengths in provider network retention, strong gross margins, and strategic investments highlight its competitive advantage and growth potential.
Challenges such as tightening growth rates and margin sustainability require proactive strategies, while opportunities in market positioning and growth avenues offer promising prospects.
With a strong pipeline, focus on enhancing services, and commitment to growth, Progyny is poised to capitalize on market demand and drive further success.

Progyny reports record Q1 growth, raises 2023 guidance amid strong demand

Progyny's Q1 2023 performance reflects robust growth, operational efficiency, and a strategic focus on expanding market reach and service offerings. Despite potential challenges, the company remains optimistic about future prospects, raising guidance for 2023 and highlighting strong demand for fertility benefits.

Progyny reports record revenue and strong growth outlook for 2023

Progyny's Q2 2023 earnings call highlighted exceptional financial performance, strong operational metrics, and a positive outlook for future growth. The company's focus on quality care, cost containment, and market trends positions it well for continued success in the reproductive health industry.
With a robust PBM model, unique contracting approach, and commitment to data-driven outcomes, Progyny stands out as a leader in the sector. The expansion into menopause services and partnerships further strengthens its competitive edge and diversifies its service offerings.
While Progyny faces challenges in market penetration and operational scalability, the company's strategic strengths and growth opportunities present a promising outlook. By navigating industry challenges and leveraging emerging trends, Progyny is poised for sustained growth and innovation.

Progyny reports record Q3 earnings, eyes growth through diversification

Progyny's Q3 performance reflects robust growth, strong client relationships, and strategic expansion initiatives.
Despite challenges in Q4 and Progyny Rx contribution decline, the company is well-positioned for sustained growth.
Opportunities lie in diversifying services, addressing economic concerns, and leveraging partnerships for future expansion.
Overall, Progyny's proactive strategies and solid financial performance signal a promising outlook for continued success.

Progyny excels in 2023, eyes diversified growth in 2024

Progyny's exceptional 2023 performance and client-focused approach position it as a leader in fertility care.
While facing revenue challenges in Q1, Progyny's strategic initiatives and market opportunities offer avenues for growth.
The company's resilience in member activity and diversified revenue streams bode well for sustained success.
Progyny's expansion plans and competitive wins underscore its strong market position and growth potential.

Progyny reports strong Q1 performance, eyes growth opportunities ahead

Progyny's Q1 showed strength but faced challenges in utilization and revenue.
The company's business model demonstrated leverage and solid financial performance.
Opportunities lie in market trends, expanding services, and employer conversations.
Guidance for Q2 and full-year adjusted EBITDA indicates growth trajectory.
Progyny's focus on women's health and family building positions it for future success.

Progyny reports 9% revenue growth in Q2 2024 earnings call

Progyny delivered solid financial performance in Q2 2024, with revenue and gross profit showing healthy growth rates.
Despite challenges in forecasting and membership growth, the company's operational strengths and cash flow generation are notable.
Adjustments to revenue guidance reflect proactive management in response to market dynamics, while opportunities for growth and efficiency improvements are evident.
Overall, Progyny's Q2 performance highlights resilience and strategic focus amidst evolving market conditions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dr. Choi brings her more than 20 years of reproductive health experience to enhance the company's current offerings and counsel on its next generation of innovations Dr. Choi brings her more than 20 years of reproductive health experience to enhance the company's current offerings and counsel on its next generation of innovations

Progyny Appoints Janet Choi, M.D., as Chief Medical Officer

NEW YORK , March 31, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Progyny, Inc. (NASDAQ: PGNY) resulting from allegations that Progyny may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Progyny securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Progyny, Inc. Investors to Inquire About Securities Class Action Investigation - PGNY

As the vendor of choice, Progyny's comprehensive benefit with proven clinical outcomes will be recommended to the more than 220 children's hospitals in the CHA network As the vendor of choice, Progyny's comprehensive benefit with proven clinical outcomes will be recommended to the more than 220 children's hospitals in the CHA network

Children's Hospital Association Selects Progyny as Exclusive Partner for Fertility and Family Building Benefits

NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) a leading benefits management company specializing in fertility and family building benefits solutions, today announced the expansion of its provider network to include reproductive urologists (RU). Patients with Progyny's comprehensive and equitable solution will now have convenient access to high-quality urological care, in addition to the existing Progyny network made up of more than 650 clinics and over 950 leading fertility specialists.

Progyny Enhances Male Fertility Offering with the Expansion of its Reproductive Urologist Network

The company reported record revenue at the beginning of the week.

Why Shares of Progyny Rose 18.4% This Week

NEW YORK , March 3, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Progyny, Inc. (NASDAQ: PGNY) resulting from allegations that Progyny may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Progyny securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Progyny, Inc. Investors to Inquire About Securities Class Action Investigation - PGNY

Alcoa

The Barron's portfolio dropped 1.2% in the past five days, compared with a 1.77% dip in the S&P 500 stock index.

A Barron's Portfolio of Stocks Outperformed This Week. Alcoa, Progyny and Other Stocks That Popped.

NEW YORK--(BUSINESS WIRE)---- $PGNY #PGNY--WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Progyny, Inc. (NASDAQ: PGNY) resulting from allegations that Progyny may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Progyny securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NATIONALLY RANKED ROSEN LAW FIRM Encourages Progyny, Inc. Investors to Inquire About Securities Class Action Investigation – PGNY

Progyny, Inc. (NASDAQ:PGNY ) Q4 2022 Earnings Conference Call February 27, 2023 4:45 PM ET Company Participants James Hart - Vice President of Investor Relations Peter Anevski - Chief Executive Officer Mark Livingston - Chief Financial Officer Michael Sturmer - President Conference Call Participants Michael Cherny - Bank of America Jailendra Singh - Truist Securities Scott Schoenhaus - KeyBanc Stephanie Davis - SVB Securities Operator Good day, ladies and gentlemen and welcome to the Progyny Inc. Fourth Quarter 2022 Earnings Call. [Operator Instructions].

Progyny, Inc. (PGNY) Q4 2022 Earnings Call Transcript

Progyny (PGNY) delivered earnings and revenue surprises of 50% and 1.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Progyny (PGNY) Q4 Earnings and Revenues Beat Estimates

Zoom Video

Big after-hours gains followed a strong day on Wall Street.

Zoom Is Zooming, But This Health-Tech Stock Is Doing Even Better

Reports Full Year Revenue of $786.9 Million, Reflecting 57% GrowthReports Record Quarterly Revenue and Operating Cash Flow of $214.3 Million and $51.5 Million, RespectivelyIssues Financial Guidance for 2023, Anticipates Crossing $1 Billion Revenue Milestone

Progyny, Inc. Announces Fourth Quarter 2022 Results

NEW YORK , Feb. 17, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Progyny, Inc. (NASDAQ: PGNY) resulting from allegations that Progyny may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Progyny securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Progyny, Inc. Investors to Inquire About Securities Class Action Investigation - PGNY

New York, New York--(Newsfile Corp. - February 16, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Progyny, Inc. (NASDAQ: PGNY) resulting from allegations that Progyny may have issued materially misleading business information to the investing public.

ROSEN, A Leading Law Firm, Encourages Progyny, Inc. Investors to Inquire About Securities Class Action Investigation - PGNY

NEW YORK, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, will report its financial results for the quarterly period and full year ended December 31, 2022 after the close of the market on Monday, February 27, 2023.

Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2022 Results Report

Atlanta, Georgia--(Newsfile Corp. - February 7, 2023) - Holzer & Holzer, LLC is investigating whether Progyny, Inc. ("Progyny" or the "Company") (NASDAQ: PGNY) complied with federal securities laws. On February 7, 2023, Spruce Point Capital Management published a report highlighting what it described as "accounting concerns related to revenue and expense recognition, as well as significant inconsistencies related to the Company's client and member disclosures."Following this report, the Company's stock price dropped.

SHAREHOLDER ALERT: Investigation of Progyny, Inc. (PGNY) Announced by Nationally Ranked Investors' Rights Firm Holzer & Holzer, LLC

Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on Progyny, Inc. (Nasdaq: PGNY)

Progyny (PGNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Progyny (PGNY) Beat Estimates Again in Its Next Earnings Report?

There is a lack of effective solution in standard fertility benefit packages and PGNY is addressing this gap. PGNY's approach drives down the overall cost.

Progyny: Expect Fast Growth Despite A Weak Macro Backdrop

Five Below

Hologic

Impinj

Yum China Hlds

These top-ranked stocks are likely to beat on bottom line in their next releases. Tap Yum China (YUMC), Impinj (PI), Five Below (FIVE), Hologic (HOLX) and Progyny (PGNY).

In Search of an Earnings Beat? Play These Top 5 Stocks

Advanced Micro Devices

Amazon

Alibaba

Enphase Energy

NVIDIA

PayPal

With a rough 2022 spilling into 2023, we're running into a broad list of stocks to avoid. Especially those in the tech space, where high-profile layoffs have picked up amid a severe slowdown in growth.

7 Stocks With a Forward P/E of 25 to Run Away From

Anticipates Results to be at the High-End of its Previously Provided Financial GuidanceAnticipates Reporting Record Fourth Quarter Operating Cash Flow of Approximately $50 Million

Progyny to Discuss its Strong 2022 Financial Performance at Upcoming Investor Conference

Kinsale Capital Group

Lovesac Company

SoFi Technologies

Three-year revenue growth rates between 39% and 54% are projected, making these stocks prime multibagger candidates.

4 Unstoppable Multibaggers to Buy in 2023 and Hold for the Next Decade

Compared to many newly listed public companies in recent years, Progyny is thriving as client count and revenues have grown tremendously. Progyny is the market leader in the fertility benefits arena, with a proven and successful management team.

Progyny: A Winner For Years To Come

New York, New York--(Newsfile Corp. - December 17, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Progyny, Inc. ("Progyny" or the "Company") (NASDAQ: PGNY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Progyny and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

News for Progyny Stock (PGNY)